Inhibition of pancreatic stellate cell activation by halofuginone prevents pancreatic xenograft tumor development

Pancreas

Volumn 39, Issue 7, 2010, Pages 1008-1015

  Spector, Itai ^a,b   Honig, Hen ^a   Kawada, Norifumi ^c   Nagler, Arnon ^d   Genin, Olga ^a   Pines, Mark ^a  

^a VOLCANI CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

collagen; cytoglobin; fibrosis; halofuginone; xenograft

Indexed keywords

CERULETIDE; COLLAGEN; CYTOGLOBIN; HALOFUGINONE; MATRIGEL; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL ACTIVATION; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PANCREAS CELL; PANCREAS TUMOR; PRIORITY JOURNAL; STELLATE CELL; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; MALE; MICE; NEOPLASM TRANSPLANTATION; PANCREAS; PANCREATIC NEOPLASMS; PANCREATIC STELLATE CELLS; PIPERIDINES; QUINAZOLINONES; TRANSPLANTATION, HETEROLOGOUS;

EID: 77957743993     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181da8aa3     Document Type: Article

References (70)

1. van Kempen LC, Ruiter DJ, van Muijen GN, et al. The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol. 2003;82:539-548.
2. Shekhar MPV, Pauley R, Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 2003;5:130-135.
3. Zalatnai A. Molecular aspects of stromal-parenchymal interactions in malignant neoplasms. Curr Mol Med. 2006;6:685-693.
4. Ronnov-Jessen L, Villadsen R, Edwards JC, et al. Differential expression of a chloride intracellular channel gene, CLIC4, in transforming growth factor-beta1-mediated conversion of fibroblasts to myofibroblasts. Am J Pathol. 2002;161:471-480.
5. Lewis MP, Lygoe KA, Nystrom ML, et al. Tumour-derived TGF-beta1 modulates myofibroblast differentiation and promotes HGF/SF-dependent invasion of squamous carcinoma cells. Br J Cancer. 2004;90:822-832.
6. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer. 2004;45(suppl 2):S163-S175.
7. Genin O, Rechavi G, Nagler A, et al. Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment? Neoplasia. 2008;10:940-948.
8. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6:392-401.
9. DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer. 2000;36:1258-1268.
10. De Wever O, Mareel M. Role of myofibroblasts at the invasion front. Biol Chem. 2002;383:55-67.
11. Tuxhorn JA, Ayala GE, Smith MJ, et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8:2912-2923.
12. Zidar N, Gale N, Kambic V, et al. Proliferation of myofibroblasts in the stroma of epithelial hyperplastic lesions and squamous carcinoma of the larynx. Oncology. 2002;62:381-385.
13. Armstrong T, Packham G, Murphy LB, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2004;10:7427-7437.
14. van Hoorde L, van Aken E, Mareel M. Collagen type I: a substrate and a signal for invasion. Prog Mol Subcell Biol. 2000;25:105-134.
15. Lockwood DS, Yeadon TM, Clouston AD, et al. 2003 Tumor progression in hepatocellular carcinoma: relationship with tumor stroma and parenchymal disease. J Gastroenterol Hepatol. 2003;18:666-672.
16. Vaquero EC, Edderkaoui M, Nam KJ, et al. Extracellular matrix proteins protect pancreatic cancer cells from death via mitochondrial and nonmitochondrial pathways. Gastroenterology. 2003;125:1188-1202.
17. Apte MV, Wilson JS. Mechanisms of pancreatic fibrosis. Dig Dis. 2004;22:273-279.
18. Jaster R. Molecular regulation of pancreatic stellate cell function. Mol Cancer. 2004;3:26-34.
19. Glass A, Kundt G, Brock P, et al. Delayed response toward activation stimuli in pancreatic stellate cells. Pancreas. 2006;33:293-300.
20. Bachem MG, Schunemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005;128:907-921.
21. Erkan M, Kleeff J, Gorbachevski A, et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology. 2007;132:1447-1464.
22. Omary MB, Lugea A, Lowe AW, et al. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J Clin Invest. 2007;117:50-59.
23. Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 2008;68:918-926.
24. Vonlaufen A, Joshi S, Qu C, et al. Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 2008a;68:2085-2093.
25. Vonlaufen A, Phillips PA, Xu Z, et al. Pancreatic stellate cells and pancreatic cancer cells: an unholy alliance. Cancer Res. 2008b;68:7707-7710.
26. Bachem MG, Zhou S, Buck K, et al. Pancreatic stellate cells-role in pancreas cancer. Langenbecks Arch Surg. 2008;393:891-900.
27. Schneider G, Siveke JT, Eckel F, et al. Pancreatic cancer: basic and clinical aspects. Gastroenterology. 2005;128:1606-1625.
28. Cohen SJ, Alpaugh RK, Palazzo I, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37:154-158.
29. Truty MJ, Urrutia R. Basics of TGF-beta and pancreatic cancer. Pancreatology. 2007;7:423-435.
30. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2007;6:1186-1197.
31. Nakatani K, Okuyama H, Shimahara Y, et al. Cytoglobin/STAP, its unique localization in splanchnic fibroblast-like cells and function in organ fibrogenesis. Lab Invest. 2004;84:91-101.
32. Fordel E, Thijs L, Martinet W, et al. Neuroglobin and cytoglobin overexpression protects human SH-SY5Y neuroblastoma cells against oxidative stress-induced cell death. Neurosci Lett. 2006;410:146-151.
33. Xu R, Harrison PM, Chen M, et al. Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther. 2006;13:1093-1100.
34. Bruck R, Genina O, Aeed H, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology. 2001;3:379-386.
35. Gnainsky Y, Kushnirsky Z, Bilu G, et al. Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tiss Res. 2007;328:153-166.
36. Zion O, Genin O, Kawada N, et al. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas. 2009;38:427-435.
37. Sheffer Y, Leon O, Pinthus JH, et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy- mediated antitumoral effect. Mol Cancer Ther. 2007;6:570-577.
38. McGaha TL, Phelps RG, Spiera H, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor- beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002;118:461-470.
39. Xavier S, Piek E, Fujii M, et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem. 2004;279:15167-15176.
40. Yee KO, Connolly CM, Pines M, et al. Halofuginone inhibits tumor growth in the polyoma middle Tantigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol Ther. 2006;5:218-224.
41. Pines M. Targeting TGFA signaling to inhibit fibroblasts activation as a therapy for fibrosis and cancer. Expert Opin Drug Dis. 2008;3:11-20.
42. Levi-Schaffer F, Nagler A, Slavin S, et al. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J Invest Dermatol. 1996;106:84-88. (Pubitemid 26053386)
43. Pines M, Domb A, Ohana M, et al. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem Pharmacol. 2001;62:1221-1227.
44. Turgeman T, Hagai Y, Huebner K, et al. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul Disord. 2008;18:857-868.
45. Abramovitch R, Dafni H, Neeman M, et al. Inhibition of neovascularization, tumor growth and facilitation of wound repair by halofuginone, an inhibitor of collagen type I synthesis. Neoplasia. 1999;1:321-329.
46. Gavish Z, Pinthus JH, Barak V, et al. Growth inhibition of prostate cancer xenografts by halofuginone. Prostate. 2002;51:73-83.
47. Pinthus JH, Sheffer Y, Nagler A, et al. Inhibition of Wilms tumor xenografts progression by halofuginone is accompanied by activation of WT1 gene expression. J Urol. 2005;174:1527-1531.
48. Kruse ML, Hildebrand PB, Timke C, et al. Isolation, long-term culture, and characterization of rat pancreatic fibroblastoid/stellate cells. Pancreas. 2001;23:49-54.
49. Neuschwander-Tetri BA, Burton FR, Presti ME, et al. Repetitive self-limited acute pancreatitis induces pancreatic fibrogenesis in the mouse. Dig Dis Sci. 2000;45:665-674.
50. Hast J, Schiffer IB, Neugebauer B, et al. Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude mice. Anticancer Res. 2002;22:677-688.
51. Ogawa M, LaRue AC, Drake CJ. Hematopoietic origin of fibroblasts/ myofibroblasts: its pathophysiologic implications. Blood. 2006;108:2893-2896.
52. Radisky DC, Kenny PA, Bissell MJ. Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT? J Cell Biochem. 2007;101:830-839.
53. Acloque H, Adams MS, Fishwick K, et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest. 2009;119:1438-1449.
54. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
55. Magness ST, Battaler R, Yang L, et al. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology. 2004;40:1151-1159.
56. Sugimoto H, Mundel TM, Kieran MW, et al. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther. 2006;5:1640-1646.
57. Talukdar R, Tandon RK. Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. J Gastroenterol Hepatol. 2008;23:34-41.
58. Ellenrieder V, Schneiderhan W, Bachem M, et al. Fibrogenesis in the pancreas. Rocz Akad Med Bialymst. 2004;49:40-46.
59. Lee H, Lim C, Lee J, et al. TGF-beta signaling preserves RECK expression in activated pancreatic stellate cells. J Cell Biochem. 2008;104:1065-1074.
60. Li L, Bachem MG, Zhou S, et al. Pancreatitis-associated protein inhibits human pancreatic stellate cell MMP-1 and -2, TIMP-1 and -2 secretion and RECK expression. Pancreatology. 2009;9:99-110.
61. Erkan M, Reiser-Erkan C, Michalski CW, et al. Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma. Neoplasia. 2009;11:497-508.
62. Schmidt M, Gerlach F, Avivi A, et al. Cytoglobin is a respiratory protein in connective tissue and neurons, which is up-regulated by hypoxia. J Biol Chem. 2004;279:8063-8069.
63. Couvelard A, O'Toole D, Leek R, et al. Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas. Histopathology. 2005;46:668-676.
64. Elkin M, Miao HQ, Nagler A, et al. Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000; 14:2477-2485.
65. Erkan M, Michalski CW, Rieder S, et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin Gastroenterol Hepatol. 2008;6:1155-1161.
66. H17 cell differentiation by activating the amino acid starvation response. Science. 2009;324:1334-1338.
67. Deval C, Chaveroux C, Maurin AC, et al. Amino acid limitation regulates the expression of genes involved in several specific biological processes through GCN2-dependent and GCN2-independent pathways. FEBS J. 2009;276:707-718.
68. Harding HP, Novoa I, Zhang Y, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6:1099-1108.
69. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans. 2006;34:7-11.
70. Blander MJ, Amsen D. Amino acid addiction. Science. 2009;324:1282-1283.